Akebia Therapeutics (AKBA) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Akebia Therapeutics (AKBA) has outperformed Upstream Bio (UPB) over the past year, losing 70.4% versus a loss of 75.3%. Upstream Bio is the larger company by market cap ($253.0 million vs $226.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | UPB |
|---|---|---|
| Share price | $0.8184 | $4.62 |
| Market cap | $226.78M | $253.04M |
| 1-day change | -6.30% | +0.22% |
| YTD return | -45.75% | -83.02% |
| 1-year return | -70.39% | -75.31% |
| 5-year return | -69.35% | — |
| EPS (TTM) | $-0.12 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $33.68 |
| 52-week low | $0.814 | $4.37 |
| Distance from 52-week high | -74.42% | -86.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +378.98% | +574.03% |
| Average volume | 6.13M | 610.08K |
| Shares outstanding | 277.11M | 54.77M |
| Employees | 194 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
AKBA vs UPB FAQ
Which is bigger, Akebia Therapeutics or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $253.04M compared with $226.78M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or UPB?
AKBA returned -70.39% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.